Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Immune Therapy for Condyloma
NCT03158480Unknown
- Sponsor
- Shenzhen Second People's Hospital
- Start
- Jun 2017
- Primary completion
- Dec 2018
- Modality
- Prophylactic Vaccines, Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Randomised, triple-blind trial in condylomata acuminata comparing DC-CIK+interferon Group with Placebo+interferon Group (2 arms). Primary endpoint: Condylomata Acuminata recurrence rate at 6 months. Status: unknown.
02
Drugs
dendritic cell vaccine + cytokine-induced killer cells
03
Conditions
condylomata acuminata
Beyond the preview
Go deeper on NCT03158480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03158480.